Um die volle Funktionalität der Webseite nutzen zu können, müssen Sie JavaScript in ihrem Browser aktivieren.

DAX19.476,21-0,35 %

Gold2.660,70+0,35 %

Öl (Brent)74,54-3,82 %

Dow Jones42.741,42-0,86 %

US Tech 10020.166,47-1,50 %

EUR/USD1,08882-0,18 %

Top 15 der gesamten Suchanfragen der letzten 7 Tage

Login

Adicet Bio Aktie

Aktie

ISIN: US0070021086 WKN: A2QESQ Land Flagge US

USA

Zur Watchlist hinzufügen Zum Portfolio hinzufügen

Zum Portfolio hinzufügen

1,2810

EUR

+0,87 %

+0,0110 EUR

Letzter Kurs 22:06:19 Lang & Schwarz

Geldkurs

22:06:19

1,2550

EUR

6.198 STK

Briefkurs

22:06:19

1,3070

EUR

6.198 STK

Adicet Bio Aktie kaufen

Neueste Nachrichten

Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) 30.09.24 · Business Wire (engl.) · Adicet Bio
Adicet Bio to Present at the American Society of Gene & Cell Therapy’s (ASGCT) 2024 Advancing Gene + Cell Therapies for Cancer Conference 30.09.24 · Business Wire (engl.) · Adicet Bio
Adicet Opens Enrollment for ADI-001 Phase 1 Clinical Trial in Autoimmune Diseases 30.09.24 · Business Wire (engl.) · Adicet Bio
Mantle Cell Lymphoma Clinical Trial Pipeline Insights Featuring 20+ Companies \| DelveInsight 19.09.24 · PR Newswire (engl.) · Incyte
ADI-001 Clinical Biomarker Data Demonstrate Robust Tissue Trafficking and Complete B Cell Depletion in Secondary Lymphoid Tissue 19.09.24 · Business Wire (engl.) · Adicet Bio
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) 30.08.24 · Business Wire (engl.) · Adicet Bio
Adicet Bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference 27.08.24 · Business Wire (engl.) · Adicet Bio
Adicet Bio Appoints Lloyd Klickstein, M.D., Ph.D. to the Board of Directors 19.08.24 · Business Wire (engl.) · Adicet Bio
Adicet Reports Second Quarter 2024 Financial Results and Provides Business Updates 13.08.24 · Business Wire (engl.) · Adicet Bio
Adicet Bio to Participate in Upcoming Investor Conferences 01.08.24 · Business Wire (engl.) · Adicet Bio
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) 31.07.24 · Business Wire (engl.) · Adicet Bio
Adicet Bio Receives FDA Fast Track Designation for ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma 08.07.24 · Business Wire (engl.) · Adicet Bio

1
2
3
…
4

Meistgelesen

30 Tage
12 Monate

ADI-001 Clinical Biomarker Data Demonstrate Robust Tissue Trafficking and Complete B Cell Depletion ... 128 Leser
Mantle Cell Lymphoma Clinical Trial Pipeline Insights Featuring 20+ Companies \| DelveInsight 112 Leser
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) 108 Leser
Adicet Opens Enrollment for ADI-001 Phase 1 Clinical Trial in Autoimmune Diseases 100 Leser
Adicet Bio to Present at the American Society of Gene & Cell Therapy’s (ASGCT) 2024 Advancing ... 100 Leser

Adicet Provides Corporate Update and Highlights Strategic Priorities for 2024 192 Leser
Adicet Bio Receives FDA Fast Track Designation for ADI-270 in Metastatic/Advanced Clear Cell Renal ... 168 Leser
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) 164 Leser
Adicet Reports First Quarter 2024 Financial Results and Provides Business Updates 160 Leser
Adicet Bio to Present at the 2023 Jefferies London Healthcare Conference 144 Leser
Adicet Bio Highlights ADI-001 Expansion, Persistence and Pharmacodynamic Profile from Ongoing Phase ... 144 Leser
Adicet Bio Announces FDA Clearance of IND Application for ADI-270 in Renal Cell Carcinoma 144 Leser
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) 140 Leser
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) 140 Leser
Adicet Bio, Inc. Announces Closing of $98 Million Public Follow-On Offering and Exercise in Full of ... 136 Leser